Cytotoxic properties of platinum(IV) and dinuclear platinum(II) complexes and their ligand substitution reactions with guanosine-5′-monophosphate

Arsenijević, Miloš; Milovanovic, Marija; Volarević, Vladislav; Čanović, Dragan; Arsenijević, Nebojša; Soldatović, Tanja; Jovanović, Snežana; Bugarčić, Živadin D.

doi:10.1007/s11243-012-9613-4

Cited by 19 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was shown that regardless of different stoichiometric ratio of the substrates, reactions of potassium tetrachloridoaurate(III) with the above mentioned ligands lead to the formation of mononuclear complexes of the general formula [AuCl 3 (az)], in which the corresponding diazine (az) acted as a monodentate ligand. This contrasted with the bidentate bridging function of diazine ligands in the analogous platinum(II) complexes [30][31][32][33][34][35][36] and was attributed to the stronger electronwithdrawing effect of Au(III) in comparison to the isoelectronic Pt(II) ion [29]. In addition, our recent study allowed to establish the correspondence between basicity of the diazine ligand and its ability to engage the uncoordinated nitrogen atom in intermolecu- lar interactions, and demonstrated inherent helicity of the investigated molecules in crystals.…”

Section: Introductionmentioning

confidence: 91%

Gold(III) complexes with phenazine and quinoxaline: The role of molecular symmetry in intra- and intermolecular interactions

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 91%

Gold(III) complexes with phenazine and quinoxaline: The role of molecular symmetry in intra- and intermolecular interactions

et al. 2015

View full text Add to dashboard Cite

“…Antitumor activity of homonuclear platinum (II) complexes with pyrazine and 4,4′‐bipyridyl bridging ligands such as [{ trans ‐Pt (NH 3 ) 2 Cl} 2 ( μ ‐pyrazine)](ClO 4 ) 2 and [{ trans ‐Pt (NH 3 ) 2 Cl} 2 ( μ − 4,4′ bipyridyl)](ClO 4 ) 2 ·dmf was lower toward human colon carcinoma HCT‐116 cell than cisplatin. [ 29 ] Some complexes with pyrazine as linker such as {[Pt(1,3‐pd)Cl] 2 ( μ ‐pz)} 2+ showed improved activity while with linker pyradizine {[Pt (en)Cl] 2 ( μ ‐pydz)} 2+ showed comparable activity to that of clinically relevant cisplatin. [ 30 ] The new isomeric azine‐bridged complexes ([{ cis ‐Pt (NH 3 ) 2 Cl} 2 ( μ ‐pzn)]Cl 2 (pzn = pyrazine) and its corresponding nitrate salt, [{ cis ‐Pt (NH 3 ) 2 Cl} 2 ( μ ‐pmn)]Cl 2 (pmn = pyrimidine), and [{ cis ‐Pt (NH 3 ) 2 Cl}2( μ ‐pdn)](NO 3 ) 2 (pdn = pyridazine) show lower cytotoxicity than cisplatin for the human tumor cell lines except for the IGROV cell line (ovarian cancer).…”

Section: Resultsmentioning

confidence: 99%

Novel heteronuclear Pt (II)‐L‐Zn (II) complexes: synthesis, interactions with biomolecules, cytotoxic properties. Two metals give promising antitumor activity?

Soldatović

Selimović

Milivojević

et al. 2020

Applied Organom Chemis

View full text Add to dashboard Cite

The novel heteronuclear complexes [{cis‐PtCl (NH3)(μ‐pyrazine)ZnCl (terpy)}](ClO4)2 (Pt‐L1‐Zn) and [{cis‐PtCl (NH3)(μ‐4,4′‐bipyridyl)ZnCl (terpy)}](ClO4)2 (Pt‐L2‐Zn) (where terpy = 2,2′:6′,2′′‐terpyridine, L1 = pyrazine, L2 = 4,4′‐bipyridyl) were synthesized and characterized. The pKa values were determined, and based on them it was established that the π‐acceptor ability of the pyrazine bridging ligand is more affective on lower pKa values. The kinetic measurements of the substitution reactions with biologically relevant ligands, such as guanosine‐5′‐monophosphate (5′‐GMP), inosine‐5′‐monophosphate (5′‐IMP) and glutathione (GSH), were studied at pH 7.4. The reactions were followed under pseudo‐first‐order conditions by UV–Vis spectrophotometry. The order of reactivity of the investigated biomolecules for the first reaction is 5′‐GMP > 5′‐IMP > GSH, while for the second is 5′‐IMP > GSH. Pt‐L1‐Zn complex is more reactive than Pt‐L2‐Zn. The cytotoxic activity of heteronuclear Pt‐L1‐Zn and Pt‐L2‐Zn complexes was determined on human colorectal cancer cell line (HCT‐116) and human breast cancer cell line (MDA‐MB‐231). Both complexes significantly reduced cell viability on tested cell lines and exerted significant cytotoxic effects, with better effect on HCT‐116 cells than cisplatin, especially after 72 hr (IC50 < 0.52 μM). The Pt‐L2‐Zn complex showed higher activity against human breast cancer cells (MDA‐MB‐231) than cisplatin after 72 hr. The higher reactivity toward DNA constituent and significant cytotoxic activity may be attributed to the different geometry, Lewis acidity of different metal centers, as well as, to choice of bridging ligands.

show abstract

“…Platinum (IV) complexes have greater inertness than the corresponding platinum (II) complexes. They have some advantages such as oral administration, reduced toxicity and a decrease in the amount of the complex that is lost or deactivated in the path to the target cell (17,18).…”

Section: History Of Platinum-based Therapymentioning

confidence: 99%

Platinum Complexes And Their Anti-Tumour Activity Against Chronic Lymphocytic Leukaemia Cells

Silconi¹,

Benazic²,

Milovanović³

et al. 2015

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

Since the discovery of the antitumor activity of cisplatin by Rosenberg and co-workers, the use of metal complexes in cancer treatment has caused a huge interest. Today, platinum-based drugs are part of standard chemotherapy in the management of a variety of ca ncers, germ cell tumours, sarcomas, and lymphomas. Unfortunately, toxicity and drug resistance are major obstacles to wider clinical application of these drugs. Their use is greatly limited by severe side effects such as nephrotoxicity, ototoxicity, and neurotoxicity. Although cisplatin is one of the most successful anticancer drugs to date, its biochemical mechanism of action is still unclear. Cisplatin is generally accepted as having the ability to interact with the purine bases on the DNA, causing DNA damage, interfering with DNA repair mechanisms, and subsequently inducing apoptosis in cancer cells. Chronic lymphocytic leukaemia is a neoplastic B cell lymphoproliferative disease characterized by a highly variable clinical course. Clinical stage at the diagnosis and biological prognostic factors are the important predictors for survival. The Rai and Binet staging systems describe three major prognostic subgroups. Commonly used prognostic biomarkers in chronic lymphocytic leukaemia can be divided into genotypic, DNA-level changes and phenotypic, expression-level changes. For chronic lymphocytic leukaemia, substantial progress in therapy has not been made over the past 40 years. The main goal of future scientific research is to find new platinum complexes that have better efficacy in cancer treatment, the ability to be administered orally, without developing a cancer-drug resistance, and reduced toxic side effects.

show abstract

Cytotoxic properties of platinum(IV) and dinuclear platinum(II) complexes and their ligand substitution reactions with guanosine-5′-monophosphate

Cited by 19 publications

References 31 publications

Gold(III) complexes with phenazine and quinoxaline: The role of molecular symmetry in intra- and intermolecular interactions

Gold(III) complexes with phenazine and quinoxaline: The role of molecular symmetry in intra- and intermolecular interactions

Novel heteronuclear Pt (II)‐L‐Zn (II) complexes: synthesis, interactions with biomolecules, cytotoxic properties. Two metals give promising antitumor activity?

Platinum Complexes And Their Anti-Tumour Activity Against Chronic Lymphocytic Leukaemia Cells

Contact Info

Product

Resources

About